Butyrate as a Major Intermediary in Gut–Brain Communication and its Therapeutic Potential in Alzheimer’s Disease: A Literature Review
Undergraduate Research in Natural and Clinical Science and Technology Journal · 13.08.2026 · 1-11
DOI: 10.26685/urncst.978 ↗Kurz gefasst
Fachartikel in der Zeitschrift Undergraduate Research in Natural and Clinical Science and Technology Journal, online erschienen am 13.08.2026. Verfasst von Warda Amir und 1 weiteren Autor:innen. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Themen: Demenz
Abstract (Originalsprache)
Introduction
Alzheimer’s disease (AD) is a progressive neurodegenerative condition characterized by tau proteindysfunction and β-amyloid (Aβ) plaque accumulation, causing cognitive decline. Recent research highlights the role of thegut-brain axis in AD, with short chain fatty acids (SCFAs), particularly butyrate, being central to this communication.Butyrate plays a key role in fueling colonocytes and modulating immune responses. Butyrate-producing bacteria are oftenreduced in AD, implicating the gut-brain axis in AD pathogenesis.
Methods
A structured search of existing literature was undertaken in order to investigate butyrate’s contribution to gut-brain communication in AD and explore the viability of manipulating the microbiome as a possible therapeutic strategy.Specifically, the database PubMed was searched from 2000 to 2025 for studies linking ‘Alzheimer’s disease’, with ‘butyrate’,‘SCFAs’, and/or ‘amyloid.’ Results: Butyrate exerts neuroprotective effects in AD by maintaining barrier integrity, enhancing neurotrophic factorsecretion, reducing oxidative stress, and modulating microglial and immune responses. In addition, it exerts an antiinflammatory role, and reduces Aβ protein aggregation, thereby targeting multiple pathological processes involved in the pathogenesis of AD. Murine models suggest the feasibility of enhancing microbial butyrate as an AD therapy.
Discussion
Recent literature shows altering gut butyrate levels to be a promising therapeutic intervention for both prevention and treatment of AD. However, the limitations of the literature used must be considered when determining the next steps in research; most studies use rodent models, many of which were all male, casting doubts on the generalizability of these findings to humans. Thus, further research should be undertaken to determine the translatability of these results.
Conclusion
Modulating the gut microbiota through interventions such as probiotics, dietary changes, and butyratesupplementation may represent a promising therapeutic avenue for treating and preventing AD, working through variousmechanisms and ultimately leading to reduced AD hallmarks and symptoms. However, further research in both female andhuman models is needed to address the limitations of the studies discussed. Another future research direction is the use ofstool sample testing as an early diagnostic tool, as changes in gut microbiota seem to precede changes in cognitive function.
Zitieren
APA
Amir, W., & Chen, Q. (2026). Butyrate as a Major Intermediary in Gut–Brain Communication and its Therapeutic Potential in Alzheimer’s Disease: A Literature Review. Undergraduate Research in Natural and Clinical Science and Technology Journal, 1-11. https://doi.org/10.26685/urncst.978
Vancouver
Amir W, Chen Q. Butyrate as a Major Intermediary in Gut–Brain Communication and its Therapeutic Potential in Alzheimer’s Disease: A Literature Review. Undergraduate Research in Natural and Clinical Science and Technology Journal. 2026:1-11. doi:10.26685/urncst.978
BibTeX
@article{Amir2026,
author = {Amir, Warda and Chen, Qiaoyi},
title = {Butyrate as a Major Intermediary in Gut–Brain Communication and its Therapeutic Potential in Alzheimer’s Disease: A Literature Review},
journal = {Undergraduate Research in Natural and Clinical Science and Technology Journal},
year = {2026},
pages = {1--11},
doi = {10.26685/urncst.978}
}
EUVIMED